The statistics for animal procedures performed in 2003 were recently released by the Home Office. They indicate that, for the second year running, there was a significant increase in the number of laboratory animal procedures undertaken in Great Britain. The species and genera used, the numbers of toxicology and non-toxicology procedures, and the overall trends, are described. The implications of these latest statistics are discussed with reference to key areas of interest and to the impact of existing regulations and pending legislative reforms.
Home Office (2004). Statistics of Scientific Procedures on Living Animals: Great Britain 2003, Cm 6291, 102 pp. London, UK: HMSO.
2.
HirstW.D., AbrahamsenB., BlaneyF.E., CalverA.R., AlojL., PriceG.W., & MedhurstA.D. (2003). Differences in the central nervous system distribution and pharmacology of the mouse 5-hydroxytryptamine-6 receptor compared with rat and human receptors investigated by radioligand binding, site-directed mutagenesis, and molecular modelling. Molecular Pharmacology64, 1295–1308.
3.
Animal Procedures Committee (2002). The Use of Primates Under the Animals (Scientific Procedures) Act (1986). Analysis of Current Trends with Particular Reference to Regulatory Toxicology, 39 pp. London, UK: APC.
4.
SmithJ.A., & BoydK.M. eds (2002). The Boyd Group Papers on The Use of Non-human Primates in Research and Testing, 59 pp. Leicester, UK: British Physiological Society.
5.
ReinhardtV. (2004). Common husbandry-related variables in biomedical research with animals. Laboratory Animals38, 213–235.
PetersonN.C., & PeaveyJ.E. (1998). Comparison of in vitro monoclonal antibody production methods with an in vivo ascites production technique. Contemporary Topics in Laboratory Animal Science37, 61–66.
8.
Anon. (2002). Research in Focus: Monoclonal Antibodies, 5 pp. London, UK: Medical Research Council. Website www.mrc.ac.uk/pdf_mon_antibodies.pdf (Accessed 15.10.04).
9.
Anon. (1998). Directive 98/8/EC of the European Parliament and of the Council of 16 February 1998 concerning the placing of biocidal products on the market. Official Journal of the European CommunitiesL123, 1–63.
10.
Parliamentary Office of Science and Technology (2004). Postnote: EU Chemicals Policy229, 4 pp. London, UK: POST.
11.
JonesP.A., BudynskyE., CooperK.J., DeckerD., GriffithsH.A., & FentemJ.H. (2001). Comparative evaluation of five in vitro tests for assessing the eye irritation potential of hair-care products. ATLA29, 669–692.
12.
HartungT., PooleS., Montag-LessingT., NibbelingR., Werner-FelmayerG., JungiT., BruggerP., CoeckeS., AabergeI., & BertholdS. (2002). Comparison and validation of novel pyrogen tests based on the human fever reaction. ATLA30, Suppl. 2, 49–51.
13.
JenkinsE.S., GrayS., & CombesR.D. (2001). Mutagenesis screens: can they be justified?ATLA29, 63–68.
14.
RobinsonV., MortonD.B., AndersonD., CarverJ.F.A., FrancisR.J., HubrechtR., JenkinsE., MathersK.E., RaymondR., RosewellI., WallaceJ., & WellsD.J. (2003). Refinement and reduction in production of genetically modified mice. Laboratory Animals37, Suppl. 1, 1–51.
KimS.K., & RulifsonE.J. (2004). Conserved mechanisms of glucose sensing and regulation by Drosophila corpora cardiaca cells. Nature, London431, 316–320.
20.
WilliamsS.N., LockeC.J., BradenA.L., CaldwellK.A., & CaldwellG.A. (2004). Epileptic-like convulsions associated with LIS-1 in the cytoskeletal control of neurotransmitter signalling in Caenorhabditis elegans.Human Molecular Genetics13, 2043–2059.
